Determinants of price setting decisions on anti-malarial drugs at retail shops in Cambodia

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Patouillard, Edith ^a   Hanson, Kara ^a   Kleinschmidt, Immo ^a   Palafox, Benjamin ^a   Tougher, Sarah ^a   Pok, Sochea ^b   O'Connell, Kate ^b   Goodman, Catherine ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b POPULATION SERVICES INTERNATIONAL   (United States)

Author keywords

Drug resistance; Malaria treatment; Price setting decisions; Retail sector

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; GENERIC DRUG; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

ARTICLE; CAMBODIA; CROSS-SECTIONAL STUDY; DRUG COST; DRUG DOSAGE FORM; DRUG MARKETING; ECONOMIC ASPECT; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; INFECTION RISK; MALARIA; PARASITE TRANSMISSION; PHARMACY; TABLET; ECONOMICS; PRIVATE SECTOR;

ANTIMALARIALS; CAMBODIA; CROSS-SECTIONAL STUDIES; HEALTH SERVICES ACCESSIBILITY; PRIVATE SECTOR;

EID: 84934965868     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0737-9     Document Type: Article

References (50)

1. Rutebemberwa E, Nsabagasani X, Pariyo G, Tomson G, Peterson S, Kallander K. Use of drugs, perceived drug efficacy and preferred providers for febrile children: implications for home management of fever. Malar J. 2009;8:131.
2. Alba S, Dillip A, Hetzel MW, Mayumana I, Mshana C, Makemba A, et al. Improvements in access to malaria treatment in Tanzania following community, retail sector and health facility interventions - a user perspective. Malar J. 2010;9:163.
3. Awor P, Wamani H, Bwire G, Jagoe G, Peterson S. Private sector drug shops in integrated community case management of malaria, pneumonia, and diarrhea in children in Uganda. Am J Trop Med Hyg. 2012;87:92-6.
4. Cohen JM, Woolsey AM, Sabot OJ, Gething PW, Tatem AJ, Moonen B. Public health. optimizing investments in malaria treatment and diagnosis. Science. 2012;338:612-14.
5. Kahabuka C, Kvale G, Hinderaker SG. Care-seeking and management of common childhood illnesses in Tanzania-results from the 2010 Demographic and health survey. PLoS One. 2013;8, e58789.
6. Nonaka D, Vongseththa K, Kobayashi J, Bounyadeth S, Kano S, Phompida S, et al. Public and private sector treatment of malaria in Lao PDR. Acta Trop. 2009;112:283-7.
7. Goodman C, Brieger W, Unwin A, Mills A, Meek S, Greer G. Medicine sellers and malaria treatment in sub-Saharan Africa: what do they do and how can their practice be improved? Am J Trop Med Hyg. 2007;77:203-18.
8. Tavrow P, Shabahang J, Makama S. Vendor-to-vendor education to improve malaria treatment by private drug outlets in Bungoma District. Kenya Malar J. 2003;2:10.
9. WHO. Emergency response to artemisinin resistance in the Greater Mekong subregion. regional framework for action 2013-2015. Geneva: World Health Organization; 2013.
10. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science. 2004;305:1124.
11. Verdrager J. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. J Trop Med Hyg. 1986;89:277-89.
12. Noedl H. Artemisinin resistance: how can we find it? Trends Parasitol. 2005;21:404-5.
13. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67.
14. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001;64:12-7.
15. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva: World Health Organization; 2010.
16. Maude RJ, Woodrow CJ, White LJ. Artemisinin antimalarials: preserving the »Magic Bullet«. Drug Dev Res. 2010;71:12-9.
17. WHO. Global report on antimalarial efficacy and drug resistance: 2000-2010. Geneva: World Health Organization; 2010.
18. WHO. Global plan for artemisinin resistance containment. Geneva: World Health Organization; 2011.
19. CNM. Treatment guidelines for malaria in the Kingdom of Cambodia. Phnom Penh: National Centre for Parasitology Entomology and Malaria Control Programme; 2000.
20. Littrell M, Gatakaa H, Phok S, Allen H, Yeung S, Chuor CM, et al. Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys. Malar J. 2011;10:328.
21. Patouillard E. An economic analysis of the market for malaria treatment in Cambodia. Department of Global Health and Development: London School of Hygiene and Tropical Medicine, University of London; 2012.
22. ACTwatch Group. Household survey report. Kingdom of Cambodia: ACTwatch Group; 2009.
23. O'Connell KA, Samandari G, Phok S, Phou M, Dysoley L, Yeung S, et al. »Souls of the ancestor that knock us out« and other tales. A qualitative study to identify demand-side factors influencing malaria case management in Cambodia Malar J. 2012;11:335.
24. Yeung S, Patouillard E, Allen H, Socheat D. Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malar J. 2011;10:243.
25. Dranove D, White WD. Emerging issues in the antitrust definition of healthcare markets. Health Econ. 1998;7:167-70.
26. Scherer FM, Ross D. Industrial market structure and economic performance. third edition edn. Boston: Houghtin Mifflin Company; 1990.
27. Demsetz H. Industry structure, market rivalry, and public policy. J Law Econ. 1973;16:1-9.
28. Bennett S. Imperfect information and hospital competition in developing countries: a Bangkok case study. London School of Economics and Political Science: University of London; 1996.
29. Nakamba P, Hanson K, McPake B. Markets for hospital services in Zambia. Int J Health Plann Manage. 2002;17:229-47.
30. Gaynor M. Competition and quality in health care markets. Foundations and Trends in Microeconomics. 2007;2:441-508.
31. Cooper Z, Gibbons S, Jones S, Macguire A. Does hospital competition saves life? evidence from the english NHS patient choice reforms. Econ J. 2011;121:228-60.
32. Goodman C, Kachur SP, Abdulla S, Bloland P, Mills A. Concentration and drug prices in the retail market for malaria treatment in rural Tanzania. Health Econ. 2009;18:727-42.
33. Russo G, McPake B. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings. Health Policy Plan. 2010;25:70-84.
34. Federal Trade Commission. Horizontal Merger Guidelines. Washington: U.S. Department of Justice; 2010.
35. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8:3-15.
36. Alba S, Hetzel MW, Goodman C, Dillip A, Liana J, Mshinda H, et al. Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective. Malar J. 2010;9:164.
37. NIS. General population census of Cambodia 2008: national report on final census results. Phnom Penh, Cambodia: National Institute of Statistics and Ministry of Planning; 2008.
38. StataCorp. Stata survey data reference manual. release 11. College Station, Texas: Stata Press; 2009.
39. Tirole J. The Theory of Industrial Organization. Washington: The MIT Press; 1988.
40. Church J, Ware R. Industrial organization: a strategic approach. Boston: The McGraw-Hill Companies; 2000.
41. Gaynor M, Vogt WB. Antitrust and competition in health care markets. Volume I. Elsevier Science B.V.: In Handbook of Health Economics; 2000.
42. WHO. WHO briefing on malaria treatment guidelines and artemisinin monotherapies. Geneva: World Health Organization; 2006.
43. IOM. Saving lives, buying time: economics of malaria drugs in an age of resistance. Washington, DC: Institute of Medicine,National Academy Press; 2004.
44. Tougher S, ACTwatch Group, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, et al. Effect of the Affordable Medicines Facility-malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet. 2012;380:1916-26.
45. AMFm Independent Evaluation Team. Independent evaluation of phase 1 of the Affordable Medicines Facility - malaria (AMFm), Multi-country independent evaluation report: final report. Calverton, Maryland and London: ICF International and London School of Hygiene and Tropical Medicine; 2012.
46. WHO. Briefing note on the AMFm for the WHO Malaria Policy Advisory Committee. Geneva: World Health Organization; 2012.
47. Sabot O, Yeung S, Pagnoni F, Gordon M, Petty N, Schmits K, et al. Distribution of artemisinin-based combination therapies through private sector channels: lessons from four country case studies. Washington: Resources for Health; 2008.
48. Kone CG, Ndonky A, Lalou R, Le Hesran JY. ACT subventionées en vente dans les officines privées: expérience du Sénégal. In: Affordable Medicine Facility - Malaria: Technical Proposal to Increase Access to Malaria Medicines Background paper 7 Summary of Field Research. Geneva: Secretariat; 2007.
49. Tougher S, Mann AG, Group AC, Ye Y, Kourgueni IA, Thomson R, et al. Improving access to malaria medicine through private-sector subsidies in seven African countries. Health Aff (Millwood). 2014;33:1576-85.
50. PSI: Findings from the Willingness-to-Pay for Malarine Survey. Phnom Penh; 2003